Identification of hepatocellular carcinoma-associated hub genes and pathways by integrated microarray analysis

Tumori

Volumn 101, Issue 2, 2015, Pages 206-214

  Liu, Fangfeng ^a   Li, Hongguang ^a   Chang, Hong ^a   Wang, Jianlu ^a   Lu, Jun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Bioinformatics; Differentially expressed genes; Hepatocellular carcinoma

Indexed keywords

BUTYRIC ACID; CADMIUM; FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ZINC ION;

ACAA1 GENE; ARTICLE; CDH1 GENE; COMPUTER PROGRAM; ECHS1 GENE; FATTY ACID METABOLISM; GENE IDENTIFICATION; GENE ONTOLOGY; HEPG2 CELL LINE; HUB GENE; HUMAN; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MT2A GENE; ONCOGENE MYC; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GENE; VALIDATION PROCESS; BIOLOGY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; JAPAN; LIVER TUMOR; ONCOGENE; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; JAPAN; LIVER NEOPLASMS; MICROARRAY ANALYSIS; ONCOGENES; PROTEIN INTERACTION MAPS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84930592195     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000241     Document Type: Article

References (48)

1. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29(36):4989-5005.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485-1491.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-2576.
4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology. 2010;51(5):1820-1832.
5. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273,e1.
6. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69(18):7385-7392.
7. Liu W, Peng Y, Tobin DJ. A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis. Peer J. 2013;1:e49.
8. Kim TH, Choi SJ, Lee YH, Song GG, Ji JD. Gene expression profile predicting the response to anti-TNF treatment in patients with rheumatoid arthritis; analysis of GEO datasets. Joint Bone Spine. 2014;81(4):325-330.
9. Wray CJ, Ko TC, Tan FK. Secondary use of existing public microarray data to predict outcome for hepatocellular carcinoma. J Surg Res. 2014;188(1):137-142.
10. Ding B, Xi Y, Gao M, et al. Gene expression profiles of entorhinal cortex in Alzheimer's disease. Am J Alzheimer's Dis Other Demen. 2014;29(6):526-532.
11. Xu J, Zhang C, Song W. Screening of differentially expressed genes associated with non-union skeletal fractures and analysis with a DNA microarray. Exp Ther Med. 2014;7(3):609-614.
12. Wang HB, Jiang ZB, Li M. Research on the Typical miRNA and Target Genes in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus Cancer with DNA Microarray. Pathol Oncol Res. 2014;20(2):245-252.
13. Yoo BK, Emdad L, Su ZZ, et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest. 2009;119(3):465-477.
14. Budhu A, Forgues M, Ye Q-H, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10(2):99-111.
15. Jia H-L, Ye Q-H, Qin L-X, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007;13(4):1133-1139.
16. Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol. 2009;3(2):101-103.
17. Budhu A, Roessler S, Zhao X, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology. 2013;144(5):1066-1075,e1.
18. Liao YL, Sun YM, Chau GY, et al. Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene. 2008;27(42):5578-5589.
19. Hodo Y, Honda M, Tanaka A, et al. Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C. Clin Cancer Res. 2013;19(7):1827-1837.
20. Xia J, Fjell CD, Mayer ML, Pena OM, Wishart DS, Hancock RE. INMEX-A web-based tool for integrative meta-analysis of expression data. Nucleic Acids Res. 2013;41(Web Server issue):W63-70.
21. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
22. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: The R Foundation for Statistical Computing; 2005.
23. Liu X, Feng R, Du L. The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett. 2010;584(14):3185-3192.
24. Banerjee S, Ghoshal S, Porter TD. Activation of AMP-kinase by policosanol requires peroxisomal metabolism. Lipids. 2011;46(4): 311-321.
25. Song MO, Freedman JH. Expression of copper-responsive genes in HepG2 cells. Mol Cell Biochem. 2005;279(1-2):141-147.
26. Shen HM, Michael N, Kim N, Storb U. The TATA binding protein, c-Myc and survivin genes are not somatically hypermutated, while Ig and BCL6 genes are hypermutated in human memory B cells. Int Immunol. 2000;12(7):1085-1093.
27. Chang Y, Wang S-X, Wang Y-B, et al. ECHS1 interacts with STAT3 and negatively regulates STAT3 signaling. FEBS Lett. 2013;587(6):607-613.
28. Janssen U, Davis EM, Le Beau MM, Stoffel W. Human mitochondrial enoyl-CoA hydratase gene (ECHS1): structural organization and assignment to chromosome 10q26.2-q26.3. Genomics. 1997;40(3):470-475.
29. Xiao C-X, Yang X-N, Huang Q-W, et al. ECHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochondrial pathway in HepG2 cells. Cancer Lett. 2013; 330(1):67-73.
30. Zhu XS, Dai YC, Chen ZX, Xie JP, Zeng W, Lin YY. Enoyl-coenzyme A hydratase, short chain 1 involved in promoting the proliferation of hepatocellular carcinoma HepG2 cells. Tumor. 2013;33(5):422-427.
31. Zhu XS, Dai YC, Chen ZX, et al. Knockdown of ECHS1 protein expression inhibits hepatocellular carcinoma cell proliferation via suppression of Akt activity. Crit Rev Eukaryot Gene Expr. 2013;23(3):275-282.
32. Culkin DJ, Gelder FB, Vick SR, et al. Evaluation of a new tumor marker for localized prostate cancer. Prostate. 1992;20(2):117-122.
33. Pinto VB, Gelder FB, Morris DM. Purification, partial characterization, and clinical evaluation of an adenocarcinoma-associated antigen. Cancer Res. 1986;46(12 Pt 1):6520-6524.
34. Marikar FM, Sun QM, Hua ZC. Production of the polyclonal anti-human metallothionein 2A antibody with recombinant protein technology. Acta Biochim Biophys Sin (Shanghai). 2006;38(5):305-309.
35. Cui Y, Wang J, Zhang X, et al. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. Biochem Biophys Res Commun. 2003;302(4):904-915.
36. Reinecke F, Levanets O, Olivier Y, et al. Metallothionein isoform 2A expression is inducible and protects against ROS-mediated cell death in rotenone-treated HeLa cells. Biochem J. 2006; 395(2):405-415.
37. Wu KJ, Grandori C, Amacker M, et al. Direct activation of TERT transcription by c-MYC. Nat Genet. 1999;21(2):220-224.
38. Grandori C, Wu K-J, Fernandez P, et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev. 2003;17(13):1569-1574.
39. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18(19):3004-3016.
40. Kim YH, Girard L, Giacomini CP, et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene. 2006;25(1):130-138.
41. Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett. 2006;237(2):155-166.
42. Zhang W, Fletcher L, Muschel RJ. The role of Polo-like kinase 1 in the inhibition of centrosome separation after ionizing radiation. J Biol Chem. 2005;280(52):42994-42999.
43. Fletcher L, Cerniglia GJ, Nigg EA, Yend TJ, Muschel RJ. Inhibition of centrosome separation after DNA damage: A role for Nek2. Radiat Res. 2004;162(2):128-135.
44. Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol. 1995;130(3):507-518.
45. Ma L, Zhao X, Zhu X. Mitosin/CENP-F in mitosis, transcriptional control, and differentiation. J Biomed Sci. 2006;13(2): 205-213.
46. Vergnolle MA, Taylor SS. Cenp-F links kinetochores to Ndel1/ Nde1/Lis1/dynein microtubule motor complexes. Curr Biol. 2007;17(13):1173-1179.
47. O'Brien SL, Fagan A, Fox EJ, et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer. 2007;120(7): 1434-1443.
48. Shigeishi H, Mizuta K, Higashikawa K, Yoneda S, Ono S, Kamata N. Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. Oral Oncol. 2005;41(7):716-722.